Ipamorelin Calculator

GHS
Default: 5mg / 2mL / 0.2mgAdjust inputs to match your vial
About

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that selectively activates the ghrelin receptor (GHS-R1a) to trigger pituitary GH release. Its defining feature is selectivity: unlike earlier GHRPs such as GHRP-2 and GHRP-6, ipamorelin produces minimal effect on cortisol, prolactin, or aldosterone secretion at typical research doses. Because the GH pulse it generates is short and pulsatile, ipamorelin is most often paired with a GHRH analogue — sermorelin, CJC-1295, or modified GRF(1-29) — in research protocols. The two-compound combination produces a synergistic GH peak that more closely resembles physiological GH pulsatility than either compound alone. Ipamorelin is not FDA-approved for any indication and remains a research-only compound; published clinical investigation has been limited.

Common vial sizes
2 mglyophilized powder
5 mglyophilized powder
10 mglyophilized powder
Reference dose ranges
0.1 mg≈ 4 U-100 units (at 5mg / 2mL)
0.2 mg≈ 8 U-100 units (at 5mg / 2mL)
0.3 mg≈ 12 U-100 units (at 5mg / 2mL)
Reconstitution

How it's typically prepared

Reconstitute with bacteriostatic water and store refrigerated at 2–8 °C. The lyophilized powder is stable for years at –20 °C; reconstituted solution is typically used within 2–4 weeks. Subcutaneous injection with a U-100 insulin syringe is the most common research route. Ipamorelin is sometimes co-formulated with CJC-1295 in a single vial — verify which is the case before drawing.

FAQ

Frequently asked questions

Why is ipamorelin preferred over GHRP-2 or GHRP-6?
Ipamorelin is more selective and does not appreciably raise cortisol or prolactin, which makes it the most commonly chosen GH secretagogue in current research literature.
Is ipamorelin FDA-approved?
No. Ipamorelin is not FDA-approved for any indication. It is researched as a tool compound in GH-axis studies and is sometimes compounded by US compounding pharmacies, though its compounded status has been challenged by FDA in recent guidance.
What is the typical ipamorelin dose used in research protocols?
Reported research doses range from 100 to 300 µg per administration, two to three times daily. The calculator above renders the equivalent insulin-syringe units at the most common reconstitution ratios.
Does ipamorelin work better alone or paired with CJC-1295?
GHRH-analogue / GHS combinations produce a larger GH pulse than either compound alone in published studies — this is why most research protocols use ipamorelin with sermorelin, CJC-1295, or modified GRF(1-29) rather than as a monotherapy.
What is the half-life of ipamorelin?
Approximately 2 hours in plasma, which is why dosing is typically repeated multiple times per day rather than given as a single daily injection.
Why is ipamorelin given multiple times per day?
Endogenous GH release is pulsatile, with multiple peaks across a 24-hour period. Multi-daily ipamorelin administration approximates this pattern more closely than once-daily dosing.
Notice

PeptideDose is an educational reference. It is not medical advice and does not replace consultation with a licensed healthcare provider. Doses shown in presets are derived from published protocols and product labels — they are not personal recommendations.